CD38 and melanoma: A breakthrough in the field was obtained by Don L. Gibbons and his team, who reported that mouse models of tumors (melanoma and lung cancer), when treated for a long period with anti-PD-1 or anti-PD-L1 therapy, developed acquired resistance that is causally related to CD38 upregulation [51].